✦ LIBER ✦

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations

✍ Scribed by Riely, Gregory J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Somatic EGFR mutations and efficacy of t

✍ Linardou, Helena; Dahabreh, Issa J.; Bafaloukos, Dimitrios; Kosmidis, Paris; Mur 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 759 KB

Efficacy of EGFR tyrosine kinase inhibit

✍ Cho, Su-Hee; Park, Lee Chun; Ji, Jun Ho; Park, Silvia; Hwang, Deok Won; Lee, Ji 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 177 KB

A new generation of EGFR tyrosine-kinase

✍ Fred R Hirsch; Paul A Bunn Jr 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 92 KB

9092 POSTER Efficacy of Tyrosine Kinase

✍ Cho, S.H. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

EGFR mutations in squamous NSCLC – Preva

✍ Berzinec, P.; Hlinkova, K.; Copakova, L.; Konecny, M.; Zavodna, K.; Cerna, M.; C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 81 KB

128PD EGFR, KRAS, PIK3CA MUTATIONS AND R

✍ Crinò, L.; Pistola, L.; Bianconi, F.; Chiari, R.; Meacci, M.; Colella, R.; Giuff 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB